Small protein may have big role in making more bone and less fat

July 02, 2008

A small protein may have a big role in helping you make more bone and less fat, researchers say.

"The pathways are parallel, and the idea is if you can somehow disrupt the fat production pathway, you will get more bone," says Dr. Xingming Shi, bone biologist at the Medical College of Georgia Institute of Molecular Medicine and Genetics.

He's found the short-acting protein GILZ appears to make this desirable shift and wants to better understand how it does it with the long-term goal of targeted therapies for osteoporosis, obesity and maybe more.

"Osteoporosis and obesity are two major public health problems, but people have no idea whether they have a connection," says Dr. Shi. Bone and fat do have a common source: both are derived from mesynchymal stem cells. Bone loss and fat gain also tend to happen with age and with use of the powerful, anti-inflammatory steroid hormones glucocorticoids. "When you age, your bone marrow microenvironment changes; the balance between the bone and fat pathway is broken," says Dr. Shi, a faculty member in the MCG Schools of Medicine and Graduate Studies. "You have more fat cells accumulate."

"The bones of elderly people or those who take glucocorticoids are yellow inside instead of red," he says. And it gets worse: in a classic vicious cycle, the more fat, the more cytokines that stimulate production of bone-destroying osteoclasts and inhibit bone-forming osteoblasts. He recently showed that even the stem cells change with age: their numbers and their ability to differentiate decrease.

Weight gain and bone loss are established side effects of glucocorticoids, whose wide-ranging uses include treatment for arthritis, asthma, infections and organ transplants. Ironically, glucocorticoids also induce a short burst of GILZ. GILZ, in turn, inhibits the transcription factor PPARã2, called the master regulator of adipogenesis, or fat production, as well as CCAAT/enhancer-binding proteins that turn on this fat-producing gene. One way GILZ does this is by binding to the regulatory region of PPARã2, Dr. Shi has shown.

To restore a healthier balance of bone and fat production, sustained GILZ action is needed. "When you permanently express GILZ, cells cannot differentiate into fat cells. Instead, you increase bone formation. People like this idea," says Dr. Shi, who has watched the mesynchymal stem cell production shift.

One point of controversy is that, at least in the lab, glucocorticoids seem to enhance bone formation. But Dr. Shi believes it's the short burst of GILZ at work there. He wants to know exactly how it works to see if it could offer a targeted therapy for osteoporosis and obesity and maybe a safer option for many who need glucocorticoids.

A recent $1.5 million, five-year grant from the National Institute of Diabetes and Digestive and Kidney Diseases is enabling Dr. Shi to further test his hypothesis about how GILZ represses PPARã2 and to see if GILZ over-expression in mice reduces PPARã2 expression and consequently increases bone and decreases fat. A long-term goal is to understand exactly how PPARã2 controls fat and bone production.

GILZ also is a powerful immune and inflammation suppressor. It inhibits two key inflammatory molecules, NF-kB and AP-1, which turn on inflammatory genes in response to cytokines, such as TNF-á and IL-1â, involved in rheumatoid arthritis and other inflammatory diseases, Dr. Shi showed in research published on the cover of the April 15 issue of Journal of Cellular Biochemistry. That study notes GILZ's potential as a novel anti-inflammatory therapy.

In fact, Dr. Shi believes GILZ is a key factor mediating the anti-inflammatory effects of glucocorticoids. A long-acting version of GILZ or a similar substance would be needed to produce, for example, a powerful new arthritis treatment minus the undesirable effects. About 50 percent of arthritis patients who take glucocorticoids develop osteoporosis, he notes, worsening an already difficulty condition worse.

People can't take GILZ now, but another long-term goal is to develop a GILZ-like pill that would dramatically reduce fat production. Dr. Shi already has developed a cell line that continuously expresses GILZ.

Medical College of Georgia

ASSESSMENT OF ADRENAL GLUCOCORTICOID FUNCTION: Which tests are appropriate for screening? (Postgraduate Medicine)
by JTE Multimedia

Overproduction or underproduction of adrenal hormones raises sticky diagnostic problems for primary care physicians. Fortunately, assessment of hypoadrenalism has been greatly simplified. On the other hand, evaluation of patients with suspected hyperadrenalism (Cushing's syndrome) can be difficult, confusing, and frustrating. Dr Hasinski reviews the options for testing these critical adrenal functions and provides up-to-date information on interpreting test outcomes and pursuing a diagnosis.

Original Publication Date: July 1998

Evidence on Ergogenic Action of Glucocorticoids as a Doping Agent Risk (The Physician and Sportsmedicine)
by JTE Multimedia

Systemic administration of glucocorticoids (GCs) is banned by the World Anti-Doping Agency (WADA) during competition. Few studies have examined the effects of GCs on exercise performance, but increasing evidence has shown that short-term GC intake enhances performance in animals and humans. However, there are many health risks associated with GC use. Based on the available evidence, as presented in this article, I conclude that GCs are doping agents and should remain on the WADA’s list of banned products. Because of the complexity of GCs, however, determining the boundaries between their medical use and abuse (eg, in sports) is a constant challenge for the WADA.

Glucocorticoids and Mood: Clinical Manifestations, Risk Factors and Molecular Mechanisms (Annals of the New York Academy of Sciences)
by Lewis L. Judd (Editor), Esther M. Sternberg (Editor)

This volume explores the effects of glucocorticoids on mood and the mechanisms mediating these effects, including aspects of the clinical effects of glucocorticoids in a variety of illnesses and in health, including molecular mechanisms, glucocorticoid resistance and sensitivity, glucocorticoid receptor polymorphisms, and implications for therapy. In light of the important clinical implications for treatment of a wide range of diseases with glucocorticoids and the potential serious side effects of depression and suicidality, it is timely that this subject be re-visited due to new research. The topics addressed include a survey of clinical features of glucocorticoid treatment and molecular and genetic factors in glucocorticoid resistance and sensitivity and are of relevance to many medical...

Glucocorticoid Hormone Action (Monographs on Endocrinology)
by J. D. Baxter (Editor), G. G. Rousseau (Editor)

Topical Glucocorticoids With Increased Benefit/Risk Ratio (Current Problems in Dermatology) (v. 21)
by H. C. Korting (Author), H. C. Korting (Editor), Howard I. Maibach (Editor)

Topical glucocorticoids are an essential part of the dermatologist's armory when dealing with inflammatory skin disease. This volume reports on current research efforts to develop new compounds with an increased benefit/risk ratio.

Glucocorticoid-Induced Osteoporosis (Frontiers of Hormone Research)
by Andrea Giustina (Editor), Alberto Angeli (Editor), Ernesto Canalis (Editor), Filippo Manelli (Editor)

Osteoporosis is one of the most clinically relevant disabling chronic disease encountered in clinical practice. A common cause of osteoporosis is glucocorticoid excess, as glucocorticoids may increase bone resorption, inhibit bone formation, have indirect actions on bone by decreasing intestinal calcium absorption and induce hypercalciuria. This book presents a comprehensive overview of the effects of glucocorticoids on bone metabolism and structure and on the diagnosis and treatment of glucocorticoid-induced osteoporosis. It aims at providing updated information on the pathogenesis, diagnosis and treatment of this often dramatic complication of glucocorticoid excess. Being one of the few publications completely devoted to glucocorticoid-induced osteoporosis it will heighten the awareness...

Glucocorticoid Receptor: Webster's Timeline History, 1971 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Glucocorticoid Receptor," including when used in literature (e.g. all authors that might have Glucocorticoid Receptor in their name). As such, this book represents the largest compilation of timeline events associated with Glucocorticoid Receptor when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including...

Glucocorticoid Effects and Their Biological Consequences (NATO Asi Series)
by Louis V. Avioli (Editor)

Glucocorticoid hormone action (Monographs on endocrinology ; v. 12)
by J.D. & ROUSSEAU, G.G. eds. BAXTER (Author)

Glucocorticoid Hormone: Mechanisms of Action
by Y. Sakamoto (Editor)